University of Maryland, Baltimore and MedImmune are pairing up for a five-year, $6 million collaboration on bioscience research.
The Gaithersburg-based drug company and the university will both put money and scientists toward joint research projects. The projects will focus on medical conditions and diseases in MedImmune’s wheelhouse, such as cardiovascular disease, respiratory problems and inflammation.
The success of MenAfriVac shows vaccines can be developed outside Big Pharma’s walls, but, in most cases, the cost of late-phase trials is too great for charities. Recognizing this, JPMorgan Chase and the Bill & Melinda Gates Foundation have set up a Big Pharma-backed investment fund.
GlaxoSmithKline ($GSK), Merck ($MRK) and Pfizer’s ($PFE) foundation are among the investors in the fund, which will back late-stage development of technologies to fight disease in low-income countries. Having raised $94 million from its initial backers, the Global Health Investment Fund (GHIF) will now start trying to give vaccines and other technologies the financial clout to navigate Phase III trials.
GL-2045 is Gliknik’s Lead Recombinant Stradomer™ Designed to Improve on Pooled Human Intravenous Immunoglobulin
Gliknik Inc., a privately held biopharmaceutical company, today announced that it has entered into an exclusive worldwide licensing agreement with Pfizer Inc. for GL-2045, Gliknik’s recombinant stradomer™, a drug candidate that is designed to replace and improve on pooled human intravenous immunoglobulin (IVIG). GL-2045 has shown promising results in a broad range of preclinical tests and is being developed as a potential treatment for a wide variety of autoimmune diseases, including those in which IVIG is clinically used.
“GL-2045 is the first of several innovative drug candidates Gliknik is advancing for people with autoimmune diseases and cancer,” said Gliknik CEO David S. Block. “We selected Pfizer as our partner to progress GL-2045 from among several interested and capable parties because of its exceptional development, manufacturing and commercial capabilities.”
Emergent Biosolutions, the maker of the only FDA-licensed anthrax vaccine, is expanding its footprint in Montgomery County, with a little bit of financial help from the state and county. Emergent is taking 50,000-square feet (the precise number was reported by the Washington Business Journal earlier this month) at 400 Professional Dr., a 129,360-square foot, five-story building here, owned by Corporate Office Properties Trust. It will be moving 112 of its current employees to the building in early 2015. Emergent plans to purchase building, which is adjacent to its current research and development facility located at 300 Professional Dr.
What is interesting about the deal is the rare glimpse it reveals about the type of state and county incentives available for such transactions: the State of Maryland contributed $2 million, Montgomery County $750,000 and the City of Gaithersburg $250,000.
At a time when many states are looking to their research universities as sources of innovation and entrepreneurship, it is great to see that the University of Maryland is finally being recognized nationally. Howard Marks, an experienced entrepreneur, created the 2013 StartEngine College Index and identified the University of Maryland College Park as the top public university. I might add that the top private university is Northwestern, a fellow member of the BIG 10, which UM is joining as of 2014.
-Brian Darmody, Associate Vice President for Corporate and Foundation Relations, University of Maryland
As the Managing Director at a tech accelerator, I face a dilemma. I need to fund the most talented people, because they’ll be most likely to build great companies. But I also need to find the hidden gems. I’m the sort of person who’s always looking for the best deals. Let me tell you, great deals almost always come from unexpected sources.
Here’s the problem: If I look for talent in the same places everyone else does — at Stanford, Harvard, and MIT — I’ll have to fight crowds of investors and even other accelerators who are trying to do the same thing I am. I don’t like lines, and I hate waiting, so I don’t go with the crowd. I try to create value where others don’t recognize it.
Anyone can have a great business idea, and now students don’t have to be enrolled in the business school to get help making their ideas a success. This semester, the business school’s Dingman Center for Entrepreneurship expanded its Innovation Fridays program to reach students of all majors. The program, which used to be advertised only to business school students, gives student entrepreneurs free consultations with successful business owners to get advice for starting their own small businesses, promoting social causes or creating new technology.
Earlier this year Sun Yat-sen University, a well-regarded institution in Guangzhou in the Guangdong province of China, announced that the university and affiliated hospitals were entering into a novel collaboration with Johns Hopkins Medicine. The agreement would see Hopkins faculty working bilaterally with Sun Yat-sen’s medical faculty both in China and at Hopkins in order to help the university become a world-class biomedical research institute. The deal has significant implications for U.S. hospitals because, facing declining revenues, international collaborations like these offer a new path for growth.
It was the 30th major, revenue-producing, international healthcare collaboration for Johns Hopkins Medicine, with several more currently under negotiation — when the rest of the world combined has perhaps a few dozen similar partnerships. One reason Hopkins is outpacing others is because it created an agile satellite unit – Johns Hopkins Medicine International (JHI) – within the much larger parent organization solely dedicated to these projects.
Northrop Grumman Corporation (NYSE:NOC) and the University of Maryland, Baltimore County’s Research Park Corporation – also known as bwtech@UMBC – hosted a ceremony today for the first graduating class of the Cyber Cync Program: AccelerEyes, Five Directions and Oculis Labs.
The event also marked the expansion of bwtech@UMBC’s Cyber Incubator program, a sign of the program’s success and the positive economic impact both initiatives are making on the region.
Newt Fowler looked across Baltimore’s Renaissance Hotel ballroom and noted who was missing from the tables.
Sure, there are plenty of leaders in today’s innovation economy in Baltimore, Fowler told the crowd Thursday at the Greater Baltimore Committee’s Economic Outlook Conference.
Baltimore’s Sage Growth Partners sees opportunity where others see a headache.
Over the past few years Sage, a health care technology consulting firm, has seen business pick up as more health care providers look for help installing and managing the new electronic record systems. CEO Don McDaniel declined to disclose the company’s revenue but said Sage has seen 50 percent annual growth for the past five years. That’s a trend he expects to continue as the company makes a move to break into consulting for startup companies in the health IT sector.
As mobile health advocates clamor for scientific proof to support their emerging field, Johns Hopkins University has introduced mHealth Evidence, an online reference tool designed to help researchers quickly locate literature demonstrating the feasibility, usability and efficacy of mobile technologies in healthcare.
After a soft launch in June, the Center for Communication Programs at Johns Hopkins Bloomberg School of Public Health in Baltimore this week formally introduced mHealth Evidence via the school’s federally funded Knowledge for Health (K4Health) project. “We wanted to have one, designated site to bring together mHealth evidence,” Heidi Good Boncana, a program officer for strategic communication, ICT and innovation in the Center for Communication Programs, told MobiHealthNews.
The National Institutes of Health has launched a major initiative to improve how basic science advances and discoveries are translated into commercially viable products that improve patient care and advance public health.
The NIH Centers for Accelerated Innovations (NCAIs), funded by the NIH’s National Heart, Lung, and Blood Institute (NHLBI), will target technologies to improve the diagnosis, treatment, management, and prevention of heart, lung, blood, and sleep disorders and diseases.
mHealth advocates are giving good early reviews to the U.S. Food and Drug Administration’s final guidance document on the regulation of mobile medical apps, with one expert calling it “an expansive document that truly seeks to deregulate our nimble and innovative industry, while ensuring patient safety.”
“The guidance goes much further than I thought it would,” said Robert Jarrin, senior director of government affairs for Qualcomm, who noted that the agency has taken a new and novel approach in launching a consumer-facing website with an adjoining list of regulated apps that may be updated on a regular basis. In addition, he said, the FDA is creating a team that will be tasked with answering public inquiries about mobile medical apps submitted through mobilemedicalapps@fda.hhs.gov.
Now on its eighth run, the NIH SBIR Phase I Program for First-Time Applicants is a very practical step-by-step, four-hour online “How-To” workshop over two evenings to help researchers, faculty members, graduate students, post-docs and entrepreneurs create a SBIR company and apply to the NIH SBIR program in December of 2013. This workshop includes a post-course review of the applicant’s proposed SBIR application by our experts before submission to the NIH. As an added benefit, your SBIR companies will be included on NCET2’s newsletters that is sent out to VCs, angel investors, Global 1000 companies, and government funders.
The NIH SBIR/STTR program is one of the federal government’s best mechanisms to continue funding innovative life science research after traditional research funding has been exhausted. The objective of the program is to dramatically increase the impact of innovations derived from original federally funded R&D, and as such is an ideal program to fund university commercialization of research through new university/faculty/student startup companies. Phase I can be for up to $150,000 for 6 months. Phase II can be for up to $1 million for 2 years. After Phase I and II, the company should have eliminated enough technical and scientific risk of the original research that the company is ready for outside investor funding or product sales in the company sustainability final Phase III of the SBIR program.
Something as mundane and common as giving and receiving compliments may be a serious challenge if you are an immigrant.
Over the years, I have learned, often the hard way, the essential importance of receiving and giving compliments, at home, at work, and in social or semi-social environment. Generally speaking, East Asian cultures tend to be more reserved in expressing appreciations or affection toward others compared to the American culture (some generalization here). We have all heard of such jokes about Asian parents singling out the only “B” in the child’s report card amidst all other “A”s and demand to know why the child had failed to get straight “A”s, while American-born parents would emphasize on the progress or efforts rather than the outcome.
Health IT groups and mobile application developers’ reaction to FDA’s release of final guidance for mobile health apps is mixed, the Baltimore Sun reports (Wells/Clarke, Baltimore Sun, 9/23).
Details of Final Rule
According to the final guidance issued Monday, FDA will focus oversight on apps that:
Were developed to be used as accessories to regulated medical devices, such as apps that allow health care providers to make diagnoses by viewing medical images on smartphones or tablets; or
Can transform mobile devices into regulated medical devices, such as apps that allow a smartphone to be used as an electrocardiography machine (iHealthBeat, 9/23).
The United States Food and Drug Administration has finally released guidelines on how it plans to regulate thousands of new health-related smartphone applications.
After months of delaying its decision, the agency has determined that the vast majority of these health-related apps pose a negligible threat to consumers. Most of these “mobile medical” apps do not need federal regulation, the FDA found, so developers and investors can breathe a bit easier.
These days, having a strategic investor or partner has become almost a matter of survival for healthcare startups. Corporate investing and partnering has really taken off over the last few years as pharma and medical device companies have opened their doors and wallets to find innovation outside of their four walls.
Bureaucracy is one of the dirty words in business. Nobody wants to publicly admit their company is bogged down with too many layers of management, or needs a dozen committees to sign off on every little decision. For a couple years now, I’ve been hearing entrepreneurs complain about suffocating bureaucracy in pharma.
A new investment fund structured by JPMorgan Chase & Co. (NYSE:JPM) and the Bill & Melinda Gates Foundation will, for the first time, allow individual and institutional investors the opportunity to finance late-stage global health technologies that have the potential to save millions of lives in low-income countries.
With $94 million committed by a pioneering group of investors – including anchor support from Grand Challenges Canada (funded by the Government of Canada), the German Ministry for Economic Cooperation and Development (acting through KfW) and the Children’s Investment Fund Foundation – the Global Health Investment Fund (“GHIF” or the “Fund”) will help advance the most promising interventions to fight challenges in low-income countries such as malaria, tuberculosis, HIV/AIDS and maternal and infant mortality. To help mitigate the risk of investing in the clinical development of new technologies, the Gates Foundation and the Swedish International Development Cooperation Agency have committed to partially offset potential losses in the Fund, which will seek a financial return for investors by targeting high-impact technologies with public health applications in both developed and emerging markets.
President Obama signed the Jumpstart Our Business Startups (JOBS) Act into law on April 5, 2012. BIO advocated strongly for this new law, which includes several important policies designed to stimulate capital formation for growing businesses, including those in the biotech industry. Some of the new policies were self-effectuating, while others are awaiting rulemaking at the SEC. Below is a summary of the relevant provisions in the new law, along with a status update on the implementation process for each.
Companies spent $294 billion on research and development performed in the United States during 2011, compared with $279 billion during 2010 (table 1). Funding from the companies’ own sources was $222 billion during 2010 and $239 billion during 2011; funding from other sources was $57 billion in 2010 and $55 billion in 2011 (table 2). Data for this InfoBrief are from the Business R&D and Innovation Survey (BRDIS), which was developed and cosponsored by the National Science Foundation and Census Bureau.
The National Institutes of Health is making available approximately $3.7 million for awards to enhance training opportunities for graduate students and postdoctoral scholars to prepare them for careers in the biomedical research workforce that could take them outside of conventional academic research.
The first set of NIH Director’s Broadening Experience in Scientific Training (BEST) awards are supported through the NIH Common Fund’s Strengthening the Biomedical Research Workforce program.
Venture capital for early-stage medical device companies is drying up. At Advamed 2013, I was able to sit down and talk to Paul Grand, managing director at Research Corporation Technologies Ventures, a life sciences firm focused primarily on medical devices. When I asked him what the three main mistakes startups make when pitching him, he sighed. His first response: “Only three?”
Ouch. So be sure to avoid these blunders when pitching VCs, startup CEOs:
Covidien President and CEO Joe Almeida said in a little more than a decade, sub-Saharan Africa could be the big opportunity for medical device companies’ solution investments.
“It is a 10- or 15-year play. . . . The middle class will rise and you will have an opportunity,” Almeida said during the CEOs Unplugged series at Advamed 2013.
At Rock Health, entrepreneurs are developing innovative products to keep us healthier, and lower medical care costs.
Ten health startups in Rock Health’s current accelerator class presented to a roomful of investors and the press today. Rock Health is a startup accelerator that focuses on health care technology.
The current class of startups are tackling huge challenges in health care, such as cancer treatment or eating disorders.
Do you love health technology? Do you want to learn more about it? Do you want to teach others and collaborate with local experts?
Call it what you want–mobile health, digital health, health IT–it’s all about using innovative technology to improve the lives of you, me, and the people we care about. Let’s build an ecosystem dedicated to making health technology part of everyday life and the standard of care! Being located in the Maryland area, we have all the pieces to the puzzle to promote innovation, collaboration, and investment in an industry that will revolutionize healthcare and impact the lives of all 7+ billion people around the world.
Join our ecosystem for the MD HealthTech Coalition Kickoff Event and hear from a panel of experts about the challenges, opportunities, and innovative solutions. More details to follow…
BioHealth Innovation (BHI) is a regionally-oriented, private-public partnership functioning as an innovation intermediary focused on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Maryland.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
These days, having a strategic investor or partner has become almost a matter of survival for healthcare startups. Corporate investing and partnering has really taken off over the last few years as pharma and medical device companies have opened their doors and wallets to find innovation outside of their four walls.
Bureaucracy is one of the dirty words in business. Nobody wants to publicly admit their company is bogged down with too many layers of management, or needs a dozen committees to sign off on every little decision. For a couple years now, I’ve been hearing entrepreneurs complain about suffocating bureaucracy in pharma.
A new investment fund structured by JPMorgan Chase & Co. (NYSE:JPM) and the Bill & Melinda Gates Foundation will, for the first time, allow individual and institutional investors the opportunity to finance late-stage global health technologies that have the potential to save millions of lives in low-income countries.
